TNFSF11 and osteoporosis: The majority of the drugs used for prevention and treatment of osteoporosis decrease the bone resorption-antiresorptive agents such as hormone replacement therapy, selective estrogen receptor modulators (SERM); Raloxifene, bisphosphonates; Alendronate, Risedronate, Ibandronate, and Zoledronic acid, human monoclonal antibody against RANKL; Denosumab [49].